Clinical trials: Parkinson
Parkinson Disease
LFP Beta aDBS Feasibility Study
The purpose of this study is to use local field potentials as control signals for adjusting DBS stimulation settings under varying patient states and to assess patient outcomes.
- Trial name
- NCT03446833
- Testing
- The LFP Beta aDBS System
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- MedtronicNeuro
Parkinson's Disease
Early Parkinson's Disease Monotherapy With CVN424
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD).
- Trial name
- NCT06006247
- Testing
- CVN424 150 mg
- Where
- 42 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cerevance Beta, Inc.
Constipation, Parkinson Disease
Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled study. Approximately 72 patients will be randomized 3:1 to treatment or placebo, with approximately 54 patients allocated to receive the…
- Trial name
- KARMET (NCT03781791)
- Testing
- Active Investigational Treatment ENT-01
- Where
- 51 sites in United States
- Volunteers
- 151 people
- Sponsor
- Enterin Inc.
Triple Negative Breast Neoplasms
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
The purpose of this study is to evaluate the safety, tolerability and clinical activity of pembrolizumab (MK-3475) in combination with six chemotherapy regimens as neoadjuvant treatment for participants with triple negative…
- Trial name
- NCT02622074
- Testing
- Pembrolizumab, Nab-paclitaxel, Anthracycline (doxorubicin)
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease
The primary objective of the study is to compare the adhesiveness of 2 different patch formulations of Rotigotine using the largest patch size of 40 cm^2, under the assumption that both patch formulations show similar…
- Trial name
- NCT02230904
- Testing
- Rotigotine (Test product PR 2.3.1), Rotigotine (Reference product PR 2.1.1)
- Where
- 11 sites in Germany
- Volunteers
- 57 people
- Sponsor
- UCB BIOSCIENCES GmbH
Parkinson's Disease, Hyperprolactinemia
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2.
- Trial name
- NCT01052948
- Testing
- Retrospective study-
- Volunteers
- 86,939 people
- Sponsor
- Pfizer
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
In this study participants with advanced/metastatic adenocarcinoma of the esophagus (EAC), squamous cell carcinoma of the esophagus (ESCC), or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction…
- Trial name
- NCT02559687
- Testing
- pembrolizumab
- Volunteers
- 121 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease With End of Dose Wearing Off
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
- Trial name
- NCT00219284
- Testing
- Carbidopa/levodopa/entacapone
- Where
- 42 sites in United States, Puerto Rico
- Volunteers
- 359 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
The purpose of this study is to compare the clinical efficacy of IPX054 to immediate-release carbidopa-levodopa in subjects with Parkinson's disease.
- Trial name
- NCT00253084
- Testing
- IPX054 200 mg, CD-LD IR
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Impax Laboratories, LLC
Advanced/Metastatic Melanoma
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)
This is a Phase 2 study to assess the efficacy, safety, and tolerability of gebasaxturev administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone…
- Trial name
- NCT04152863
- Testing
- Gebasaxturev IV, Gebasaxturev ITu, Pembrolizumab
- Where
- 30 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Open-label Trial in Parkinson's Disease (PD)
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
- Trial name
- TEMPO-4 (NCT04760769)
- Testing
- Tavapadon
- Where
- 140 sites in United States, Australia and 12 more
- Volunteers
- 992 people
- Sponsor
- AbbVie
Parkinson Disease Dementia
To Evaluate the Safety of DBS in Patients With Primary Parkinson's Disease
To evaluate the safety of implantable rechargeable computer deep nerve stimulation system produced by Jiangsu Changyida Medical Technology Co., Ltd. for patients with primary Parkinson's disease
- Trial name
- NCT06494956
- Testing
- Implant device
- Volunteers
- 3 people
- Sponsor
- Jiangsu CED Medtech Co., Ltd
Parkinson Disease
Relative Bioavailability and Bioequivalence of Opicapone
the purpose assess the relative bioavailability and bioequivalence of two active pharmaceutical ingredient (API) sources of opicapone (OPC, Ongentys® and BIA 9-1067) following single 50 mg dose administration under fasting…
- Trial name
- NCT03820037
- Testing
- Ongentys, BIA 9-1067 (test)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease, Psychotic Disorders
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease.
- Trial name
- NCT00125138
- Testing
- Melperone HCl
- Where
- 21 sites in United States, India and 1 more
- Volunteers
- 90 people
- Sponsor
- Lundbeck LLC
Triple Negative Breast Neoplasms
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative…
- Trial name
- NCT04191135
- Testing
- Pembrolizumab, Olaparib, Carboplatin
- Where
- 122 sites in United States, Canada and 13 more
- Volunteers
- 462 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally…
- Trial name
- SmIle (NCT06003608)
- Testing
- Fluid biopsy capsule, Levodopa-Carbidopa Immediate Release
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Parkinson
Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
The objectives of this study were to characterize the effects of food on the pharmacokinetics (PK) and tolerability of BIA 9-1067 in healthy male subjects.
- Trial name
- NCT02071823
- Testing
- BIA 9-1067
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease, Psychoses
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
- Trial name
- NCT00095810
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson Disease, Parkinson's Disease
A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.
The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
- Trial name
- NCT07629115
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Innopeutics Corporation
Parkinson Disease, Amyotrophic Lateral Sclerosis
Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's…
- Trial name
- PROBE (NCT05542576)
- Testing
- AMDX2011P
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Amydis Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.